Literature DB >> 7811680

Characteristics of teens tested for HIV in a metropolitan area.

A E Ilegbodu1, M L Frank, A N Poindexter, D Johnson.   

Abstract

PURPOSE: This article describes the status of HIV infection in an adolescent population attending publicly supported HIV testing clinics in Houston.
METHODS: Records were reviewed of 4017 teenagers receiving HIV counseling and testing services over a period of three years (January 1990 to December 1992). We analyzed demographic characteristics, risk exposure groups, results of HIV antibody testing, and post-test counseling return rates.
RESULTS: An overall seroprevalence rate of 10.2 per 1000 was observed, with the majority of cases seen among black females. Forty-nine percent of teens with the virus failed to acknowledge a risk factor, but of those who did, male-to-male sexual contact was the most frequently reported. None who tested positive reported injected drug use. The majority of teens tested never returned to obtain their test results and post-test counseling.
CONCLUSIONS: In order to reinforce preventive behavior, institutional and other barriers should be examined and priority given to contacting both seropositive and high-risk clients who have sought testing. Interventions that encourage condom use or address sexual behavior may be more beneficial to teens than those that simply focus on drug use.

Entities:  

Mesh:

Year:  1994        PMID: 7811680     DOI: 10.1016/1054-139x(94)90495-o

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  2 in total

1.  The impact of parental consent on the HIV testing of minors.

Authors:  T M Meehan; H Hansen; W C Klein
Journal:  Am J Public Health       Date:  1997-08       Impact factor: 9.308

2.  HIV testing preferences among young men of color who have sex with men.

Authors:  Alwyn Cohall; Sheila Dini; Andrea Nye; Bonnie Dye; Natalie Neu; Christel Hyden
Journal:  Am J Public Health       Date:  2010-01-14       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.